Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics (Nasdaq: BIOR), a biotech company focused on reimagining therapeutic delivery, has announced it will report its financial results for the second quarter of 2024, which ended on June 30. The company will also provide a corporate update during a webcast and conference call scheduled for Monday, August 12, 2024, after the financial markets close.
The conference call will take place at 4:30 PM Eastern time / 1:30 PM Pacific time. Interested parties can access the call using the following details:
- Domestic: 1-877-423-9813
- International: 1-201-689-8573
- Conference ID: 13747616
Biora Therapeutics (Nasdaq: BIOR), un'azienda biotech che si propone di ripensare la somministrazione terapeutica, ha annunciato che riporterà i suoi risultati finanziari per il secondo trimestre del 2024, conclusosi il 30 giugno. La società fornirà anche un aggiornamento aziendale durante una webcast e una conference call programmata per lunedì 12 agosto 2024, dopo la chiusura dei mercati finanziari.
La conference call si svolgerà alle 4:30 PM ora orientale / 1:30 PM ora del Pacifico. Le parti interessate possono accedere alla chiamata utilizzando i seguenti dettagli:
- Nazionali: 1-877-423-9813
- Internazionali: 1-201-689-8573
- ID conferenza: 13747616
Biora Therapeutics (Nasdaq: BIOR), una empresa biotecnológica enfocada en reinventar la entrega terapéutica, ha anunciado que informará sus resultados financieros del segundo trimestre de 2024, que terminó el 30 de junio. La compañía también proporcionará una actualización corporativa durante una transmisión web y una llamada de conferencia programada para el lunes 12 de agosto de 2024, después del cierre de los mercados financieros.
La llamada de conferencia se llevará a cabo a las 4:30 PM hora del este / 1:30 PM hora del pacífico. Las partes interesadas pueden acceder a la llamada utilizando los siguientes detalles:
- Nacional: 1-877-423-9813
- Internacional: 1-201-689-8573
- ID de conferencia: 13747616
Biora Therapeutics (Nasdaq: BIOR)는 치료 제공 방식을 재구상하는 데 초점을 맞춘 생명공학 회사로, 2024년 2분기 재무 결과를 보고할 것이라고 발표했습니다. 이 보고서는 6월 30일에 종료된 분기와 관련이 있습니다. 회사는 또한 기업 업데이트를 제공할 예정이며, 이는 2024년 8월 12일 월요일으로 예정된 웹캐스트 및 콘퍼런스 콜에서 진행됩니다. 이 통화는 금융 시장이 마감된 후에 이루어집니다.
콘퍼런스 콜은 동부 표준시 기준 오후 4시 30분 / 태평양 표준시 기준 오후 1시 30분에 진행됩니다. 관심이 있는 분은 다음 세부정보를 사용하여 콜에 접속할 수 있습니다:
- 국내: 1-877-423-9813
- 국제: 1-201-689-8573
- 콘퍼런스 ID: 13747616
Biora Therapeutics (Nasdaq: BIOR), une entreprise biopharmaceutique axée sur la réinvention de la délivrance thérapeutique, a annoncé qu'elle publiera ses résultats financiers pour le deuxième trimestre de 2024, qui s'est terminé le 30 juin. La société fournira également une mise à jour corporative lors d'un webinaire et d'une conférence téléphonique prévus pour lundi 12 août 2024, après la fermeture des marchés financiers.
La conférence téléphonique aura lieu à 16h30 heure de l'Est / 13h30 heure du Pacifique. Les parties intéressées peuvent accéder à l'appel en utilisant les détails suivants :
- National : 1-877-423-9813
- International : 1-201-689-8573
- ID de conférence : 13747616
Biora Therapeutics (Nasdaq: BIOR), ein Biotech-Unternehmen, das sich darauf konzentriert, die therapeutische Abgabe neu zu gestalten, hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das zweite Quartal 2024, das am 30. Juni endete, berichten wird. Das Unternehmen wird auch ein Unternehmensupdate während eines Webcasts und einer Telefonkonferenz präsentieren, die für Montag, den 12. August 2024 nach Börsenschluss angesetzt ist.
Die Telefonkonferenz findet um 16:30 Uhr Eastern Time / 13:30 Uhr Pacific Time statt. Interessierte Parteien können über die folgenden Details auf die Konferenz zugreifen:
- Inland: 1-877-423-9813
- International: 1-201-689-8573
- Konferenz-ID: 13747616
- None.
- None.
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the second quarter ended June 30, 2024. Company management will host a webcast and conference call on Monday, August 12, 2024, after the close of financial markets.
| Conference Call and Webcast Information | |
| Date: | Monday, August 12, 2024 |
| Time: | 4:30 PM Eastern time / 1:30 PM Pacific time |
| Conference Call: | Domestic 1-877-423-9813 International 1-201-689-8573 Conference ID 13747616 Call me for instant telephone access |
| Live Webcast: | https://investors.bioratherapeutics.com/events-presentations |
A replay will remain available for 60 days on the company’s website.
About Biora Therapeutics
Biora Therapeutics is a clinical-stage biotech developing two smart pill-based therapeutics platforms: the NaviCap™ platform for colon-targeted treatment of IBD, designed to improve patient outcomes through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ platform for oral delivery of large molecules, designed to replace injection with needle-free delivery for better management of chronic diseases.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or X.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, including those involving BT-600 and our NaviCap platform and model projections, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “envision,” “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “projects,” “projecting,” “potential,” “plan,” “goal(s),” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, our ability to maintain our listing on the Nasdaq Global Market, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) and other subsequent documents, including Quarterly Reports on Form 10-Q, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
IR@bioratherapeutics.com
(646) 627-8390
Media Contact
Liz Robinson
CG Life
lrobinson@cglife.com
FAQ
When will Biora Therapeutics (BIOR) report its Q2 2024 financial results?
What is the date and time of Biora Therapeutics' (BIOR) Q2 2024 earnings call?
How can investors access Biora Therapeutics' (BIOR) Q2 2024 earnings call?
Will there be a replay available for Biora Therapeutics' (BIOR) Q2 2024 earnings call?
